Breast Cancer Stamp Debuts in June

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

WASHINGTON--The US Postal Service will release its Breast Cancer Awareness stamp on June 15, in conjunction with the 1996 National Race for the Cure, the 5K race that raises money to fund breast cancer research, education, treatment, and screening.

WASHINGTON--The US Postal Service will release its Breast CancerAwareness stamp on June 15, in conjunction with the 1996 NationalRace for the Cure, the 5K race that raises money to fund breastcancer research, education, treatment, and screening.

Race for the Cure was founded by the Susan G. Komen Breast CancerFoundation, established in 1982 by Nancy Brinker in memory ofher sister Susan G. Komen, who died of breast cancer at the ageof 36.

Sale of the stamp will launch a 4-month public service campaignduring which the Postal Service will join with the YWCA's ENCOREplusprogram, the American Cancer Society, Lifetime Television, andseveral breast cancer groups in providing information and mammographyscreenings at neighborhood post offices and other community locations.

The NCI's Cancer Information Service toll-free number (1-800-4-CANCER)will be printed on the top border of each sheet of 20 stamps.One hundred million stamps will be printed.

Recent Videos
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content